Menu ×

HEALTHCARE & PHARMACEUTICAL

Non-Invasive Prenatal Testing (NIPT) Market Segmentation By Product Type (Consumables, Disposables, Assay Kits & Reagents, Next-Generation Sequencing System, PCR Instruments, Ultrasound Devices, Microarrays and Others); By Test Type (MaterniT21 PLUS, NIFTY, Harmony test, Prena Test, Panorama Test, Verifi and others); By Method; By Application (Microdeletion Detection, Trisomy Detection & Others); By End User (Diagnostic Laboratories & Hospitals) - Demand Analysis & Opportunity Outlook 2027

  • Text Size:

Global Non-Invasive Prenatal Testing Market Overview

Non-invasive prenatal testing is also sometimes known as non-invasive prenatal screening which is a method of identifying and determining the potential risks that the fetus will be born with several genetic abnormalities. In other words, the non-invasive prenatal testing is a highly sensitive test which screens for any kind of abnormalities in a baby. Sometimes, the baby’s DNA passes into the bloodstream of mother during the phase of pregnancy. The non-invasive prenatal testing is used to analyze several genetic information contained in the DNA for a number of abnormalities. It is highly sensitive for Down’s syndrome and is also effective for Turners syndrome, Patau syndrome and Edwards syndrome.

During the non-invasive prenatal testing, the DNA from the fetus and mother is extracted from the blood sample of mother. This test is recommended for women who have the risk factors of having a baby who have a negative chromosomal condition. This testing is also advised for a women who have Rh negative blood type whereas the fetus have Rh positive. This issue is dangerous if the mother is having a child during subsequent pregnancies.

The non-invasive prenatal testing effectively uses small DNA fragments which are circulating in the blood of a pregnant woman. These shorter fragments of DNA have 200 base pairs and arise when the cell dies which results in breakage. The broken fragments are then eventually released in the bloodstream. At the time of pregnancy, bloodstream of mother contains a mixture of cfDNA which comes from her cells and from placenta. The analysis of cfDNA from placenta gives an opportunity for the early detection of several types of genetic abnormalities.

Market Size and Forecast

The market is observing vibrant growth on account of increasing number of women opting for late pregnancy along with growing prevalence of diseases. Rising incidence rate of Down’s syndrome in babies and increasing preference of non-invasive techniques are some of the factors which are supporting the growth of the market. Additionally, growing technological advancements and increased healthcare expenditure is also expected to support the growth of the market in upcoming years. The non-invasive prenatal testing market is anticipated to record a CAGR of around 17.5% over the forecast period i.e. 2019-2027.CLICK TO DOWNLOAD FREE SAMPLE REPORT

non-invasive prenatal testing market Graph

Growth Drivers

Increasing Incidence of Down ’s syndrome

The prevalence of infants born with the Downs syndrome has increased drastically which can be attributed to late pregnancy. Infants with Down syndrome usually suffer from heart defects, vision problems, respiratory disorders and many more. The non-invasive prenatal testing helps to detect any kind of genetic disorders beforehand. Therefore, the increasing prevalence of Down’s syndrome is anticipated to augment the growth of the market over the forecast period.

Large Number of Women Opting for Late Pregnancy

There is a large population of women who are opting for late pregnancy. Many women are becoming first time mothers at the age of 35 or older. Most of the child births take place in women between the ages of 30 and 40. The late pregnancy could result in many types of problems which primarily includes genetic alterations. Women opting for late pregnancy is one of the major factors which are expected to support the growth of the market over the forecast period.

Restraints

Strict Government Regulations

There are strict regulations enforced by the government such as following specific norms for delivering quality medical devices and to maintain appropriate accuracy. The manufacturers dealing with this market have to follow set standards of the medical devices affiliation. These factors are anticipated to restrain the growth of the market over the forecast period.

Market Segmentation

Our-in depth analysis of the global non-invasive prenatal testing market includes the following segments:

By Product Type

  • Consumables
  • Disposables
  • Assay Kits & Reagents
  • Next-Generation Sequencing System
  • PCR Instruments
  • Ultrasound Devices
  • Microarrays
  • Others

By Test Type

  • MaterniT21 PLUS
  • NIFTY
  • Harmony test
  • PrenaTest
  • Panorama test
  • Verifi
  • Others

By Method

  • Cell-Free DNA in Maternal Plasma Tests
  • Biochemical Screening Tests
  • Ultrasound Detection
  • Fetal Cells in Maternal Plasma Tests

By Application

  • Microdeletion Detection
  • Trisomy Detection
  • Others

By End User

  • Diagnostic Laboratories
  • Hospitals

By Region

On the basis of regional analysis, global non-invasive prenatal testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

North America is expected to dominate the global non-invasive prenatal testing market on account of increasing incidence of chromosomal abnormalities, growing technological developments, rising healthcare expenditure along with growing rate of late pregnancy.

The Asia Pacific region is also expected to have a substantial market share on the back of increasing awareness among people regarding chromosomal abnormalities, advanced maternal age and rapidly growing healthcare sector.

The global non-invasive prenatal testing market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Key Players

  • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • E Healthcare
  • Koninklijke Philips N.V.
  • Pacific Biosciences of California, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Berry Genomics Co. Ltd.
  • Illumina Inc.
  • Quest Diagnostics Incorporated
  • Other Prominent Players
Factors Covered for Market Penetration
Factors to be Considered for maximum ROI
Connect with our Analyst

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2019 Research Nester. All Rights Reserved

paypal visa americanexpress discover mastercard wire-transfer DMCA